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The physiologic function of carnitine, oxidation of fatty acid and lipid
metabolism, is severely affected in carnitine deficiency, secondary
forms of which lead to renal tubular disorders and chronic renal
failure. Reduction in serum carnitine has been frequently reported
in patients and experimental animals treated with antiepileptic drugs,
one of which, valproic acid has consistently been found to cause the
deficiency; the antiepileptic drugs, valproic acid, has consistently
been found to cause the deficiency. Previous results, however, regarding
the effects of other antiepileptic drugs have been less consistent.
Considering the controversial results available in lterarure, the aim of
this study was to determine the effect of Valproic acid, Carbamazepine
and Phenobarbital on serum carnitine levels in epileptic children.
Methods:
In the present study, serum carnitine levels were randomly monitored
before and six months after therapy in 39 epileptic patients receiving
the antiepileptic drugs mentioned. Patient blood samples were taken
before and six months after treatment and L-carnitine level was
determined using the UV enzymatic test (Rouche Kit) spectronic
Genesis 2, 340 nm.
Results:
Results showed a significant fall in the L-carnitine levels of epileptic
children taking these drugs (P< 0.01).
Conclusion:
Considering the reducing effect of antiepileptic drugs on serum
carnitine levels, it is recommended that a carnitine supplement be
administered in pediatric epileptic patients to prevent the deficiency
and related consequences caused by such therapies.
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The amino acid derivative carnitine is present in most human tissues; its major
sources are the diet and de novo synthesis. Blood carnitine increases during the
first month of life and remains in the body in adequate amounts for life. The first
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known physiologic function of carnitine is the transport
of long-chain fatty acids across the mitochondria for beta
oxidation (1,2). A subnormal concentration of total
carnitine may result from decreased biosynthesis,
inadequate dietary intake, inadequate absorption, defective
tissue transport, excessive renal excretion or inborn errors
of metabolism (3).
A number of clinical studies have shown a significant
decrease in blood carnitine concentration in patients
taking multiple antiepileptic drugs (AED), including
Valproic acid (VPA), Carbamazepine (CZB),
Phenobarbital (Ph) (4). In most studies, serum carnitine
levels of patients treated with antiepileptic drugs have
been compared with levels of control subjects, but not
with level in the same patients before treatment. This
may lead to erroneous interpretations, since in some
epileptic patients serum carnitine concentrations may be
affected by underlying metabolic or nutritional states (5-
7). Reductions in serum carnitine levels have been
frequently reported in patients and experimental animals
treated with antiepileptic drugs (4,8-10). In the work
reported here, serum carnitine levels were monitored in
epileptic children, before and 6 months after treatment
using antiepileptic drugs, viz. the three antiepileptic drugs
Valproic acid, Carbamazepine, and Phenobarbital
used in this study; and the effects were studied.
Materials and methods:
Thirty-nine children, aged between 1 month and 18 years,
were enrolled in the study. All had been referred to the
neuropediatrics division of the Ekbatan hospital in
Hamadan. Patients with metabolic disorders (such as
amino acidopathies, organic acidopathies , or suspected
mitochondria disease) , or with serious encephalopathy
or malnutriotion , were excluded (11). The patients were
divided into three groups, depending on treatment
received: (11) Group 1 consisted of 13 patients aged 2.5
years to 18 years (mean 7.9   4.8 years) , 10 with
generalized seizures including 4 with typical absence
seizures , 6 with tonic clonic seizures , 2 with complex
febrile seizures and 1 with complex partial seizures
received valproic acid ,  group 2 of 13 patients aged
between 1 to 6 years (mean 3.34   1.62) , all with partial
seizures including 9 with simple partial seizures and 4
with complex partial seizures received carbamazepine,
and group 3 of 13 patients aged between 1 to 36 months
(mean 13.15   12.19 months) 4 with tonic clonic seizures
, 7 with complex febrile seizures, 1 with simple partial
seizures and 1 with complex partial seizures , received
Phenobarbital .
Serum carnitine level was randomly monitored before
and six months after therapy. Blood samples, obtained
with informed parental consent, were taken early in the
morning after fasting for 8 hours for determination of L-
carnitine level, using the UV enzymatic test (Rouche
Kit) spectronic Genesis 2 , 340nm; analyses were done
in the biochemistry department , faculty of medicine,
Hamadan university.
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Table 1 : Mean serum carnitine levels before and during antiepileptic therapy with valroic acid
, carbamazepine or phenobarbital
* Paired Samples test
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As is shown in table (2) based on ANOVA parametric test, no difference was observed regarding to consumption of
the mentioned drugs (P>0.05).
Table 2: The comparison of the reduction of serum carnitine levels in epileptic children before and six
months after treatment with (mentioned drugs)
* One way analysis of variances (ANOVA)
Statistical analysis: Data were expressed as mean
   standard deviation. Independent samples t-test was
used to compare blood L-carnitine level in the patients
before and six months after treatment. One-way analysis
of variances was used to compare the amount of reduction
of serum carnitine level in epileptic children. Statistical
significance was considered to be a P. value of less than
0.05.
Results:
Table 1 shows serum carnitine levels in epileptic children
before and six months after treatment with antiepileptic
drugs. We observed that serum carnitine level reduced
significantly in comparison with pretreatment levels and
the difference based on the t-test was statistically
significant (P<0.01).
Discussion:
Reduction in serum carnitine levels have been frequently
reported in patients and experimental animals treated
with antiepileptic drugs (12). Because of controversial
research results, further research in humans in the field
is warranted. The present results indicate that a drop
serum L-carnitine level (with respect to pretreatment
levels in the same patient) occurs not only in patients
treated with valproic acid, but also in patients treated
with carbamazepine or Phenobarbital and the difference
is statistically significant (P<0.01).
Fung EL, et al reported that carnitine levels were lower
in patients taking valproate. They concluded that routine
monitoring of carnitine level was justified in pediatric
patients taking valproate (13). In a study done by Zelink
et al serum carnitine was measured longitudinally before
and after therapy in patients receiving valproic acid, 14
patients receiving carbamazepine and patients receiving
Phenobarbital. The patients who received valproic acid
showed a significant reduction in carnitine (P<0.001).
Such an effect however, was not found in patients
receiving carbamazepine or phenobarbital (9). Gastro
Gago et al reported serum levels of free, acyl , and total
carnitine were determined in 32 patients with seizures ,
before and after treatment with valproic acid (17 patients)
, carbamazepine (10 patients) , or Phenobarbital (5
patients). In all the three treated groups, carnitine levels
showed a significant decline with respect to pretreatment
levels (11). These findings suggest a need to monitor
serum carnitine levels in children treated with any of
these drugs. Hiraoka A. reported that reduction in the
blood free carnitine (FC) level as a side effect of sodium
valporate given to epileptic patients was pharmaco
kinetically studied in connection with changes in the
VPA disposition. The serum FC level in patients taking
at least one of Phenobarbital or phenytoin (PHT) or
carbamazeoine in addition to VPA was significantly lower
than in controls given only any one of these antiepileptic
drugs . Patients medicated only with VPA also tended to
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have a lower serum free carnitine level than the controls,
although the difference was not significant (4).
Comparing the reduction of serum carnitine level in
epileptic children, based on ANOVA parametric test, no
difference was observed regarding consumption of the
mentioned drugs (P>0.05). We did not find any significant
correlation between age and serum carnitine levels,
although such a correlation (level increasing with age)
has been detected in a previous large sample study (14).
Conclusion:
The present results thus recommend the monitoring of
serum levels of free and total carnitine not only in children
undergoing treatment with valproic acid , but also in
those undergoing treatment with carbamazepine or
phenobarbital . Monitoring should ideally begin before
treatment starts, so that subjects may act as their own
controls. This is important, since serum carnitine level
may differ from one individual to another because of
certain factors including age, nutrition and metabolic
status (15-17). In case of confirmation of carnitine
deficiency or insufficiency, one recommendation would
be to administer an oral L-carnitine supplement.
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